# Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion

> **NCT00422201** · PHASE2 · TERMINATED · sponsor: **HRA Pharma** · enrollment: 18 (actual)

## Conditions studied

- Cushing's Syndrome

## Interventions

- **DRUG:** Mifepristone

## Key facts

- **NCT ID:** NCT00422201
- **Lead sponsor:** HRA Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-05-15
- **Primary completion:** 2012-04-04
- **Final completion:** 2012-04-04
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2019-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00422201

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00422201, "Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00422201. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*